ArriVent BioPharma, Inc. financial data

Symbol
AVBP on Nasdaq
Industry
Pharmaceutical Preparations
Location
18 Campus Blvd., Suite 100, Newtown Square, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.12K %
Debt-to-equity 4.77 %
Return On Equity -28 % -151%
Return On Assets -26.7 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 34M shares +1.56%
Common Stock, Shares, Outstanding 33.7M shares +1128%
Entity Public Float 384M USD
Common Stock, Value, Issued 3K USD
Weighted Average Number of Shares Outstanding, Basic 31.5M shares +1370%
Weighted Average Number of Shares Outstanding, Diluted 31.5M shares +1370%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 79M USD +21.8%
General and Administrative Expense 15.3M USD +57.7%
Operating Income (Loss) -94.3M USD -26.4%
Net Income (Loss) Attributable to Parent -80.5M USD -16.1%
Earnings Per Share, Basic -2.56 USD/shares +92.1%
Earnings Per Share, Diluted -2.56 USD/shares +92.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 74.3M USD -50.6%
Assets, Current 227M USD +41.9%
Operating Lease, Right-of-Use Asset 154K USD -47.1%
Other Assets, Noncurrent 126K USD +17.8%
Assets 275M USD +68.6%
Accounts Payable, Current 3.78M USD -16.5%
Employee-related Liabilities, Current 4.16M USD +24.2%
Accrued Liabilities, Current 13.3M USD +91.7%
Liabilities, Current 17.3M USD +48.6%
Operating Lease, Liability, Noncurrent 14K USD -92.1%
Liabilities 17.3M USD +46.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -211K USD
Retained Earnings (Accumulated Deficit) -238M USD -51%
Stockholders' Equity Attributable to Parent 258M USD
Liabilities and Equity 275M USD +68.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.6M USD -10.3%
Net Cash Provided by (Used in) Financing Activities 186M USD +313%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 33.7M shares +1128%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 167M USD +495%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 74.3M USD -50.6%
Deferred Tax Assets, Valuation Allowance 68.8M USD +55.9%
Deferred Tax Assets, Gross 68.8M USD +55.8%
Operating Lease, Liability 176K USD
Lessee, Operating Lease, Liability, to be Paid 187K USD
Operating Lease, Liability, Current 162K USD +15.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 14K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 173K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11K USD
Deferred Tax Assets, Operating Loss Carryforwards 16.7M USD +78.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 496M USD +10566%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 39K USD -44.3%
Share-based Payment Arrangement, Expense 3.21M USD +258%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%